LANTHEUS HOLDINGS INC

Company Overview

Lantheus Holdings Inc. is a radiopharmaceutical-focused healthcare company (sector: Healthcare; industry: Drug Manufacturers - Specialty & Generic) that develops, manufactures and commercializes diagnostic and therapeutic imaging agents, device software and biomarker solutions. Its principal commercial drivers are PYLARIFY (F‑18 PSMA PET for prostate cancer) and DEFINITY (ultrasound microbubble), supported by a network of 62 activated PET manufacturing facilities, in‑house finishing/manufacturing and third‑party contract manufacturers. Management has been investing heavily in R&D and inorganic growth (Life Molecular, Evergreen) to broaden neurology, theranostic and CDMO capabilities while managing material risks such as reimbursement shifts, Mo‑99/Xenon supply concentration and PYLARIFY exclusivity expiry in 2026.

Executive Compensation Practices

Compensation is likely to follow sector norms—a mix of base salary, annual cash incentives tied to commercial and financial metrics (revenue, gross profit, operating income/cash flow) and long‑term equity (RSUs, options and performance awards) tied to regulatory and commercial milestones. At Lantheus these metrics will specifically emphasize PYLARIFY and DEFINITY volume/price, successful NDA/approval outcomes (e.g., MK‑6240 and new F‑18 PSMA submissions), integration milestones from acquisitions and free cash flow/covenant compliance given the $750M revolver and $575M of convertible notes. The company’s recent jump in stock‑based compensation, accelerated vesting tied to the Evergreen acquisition and large contingent milestone exposures (management cites potential payments up to ~$3.7B) make milestone/retention awards and deal‑related vesting protections likely features of executive pay.

Insider Trading Considerations

Insider trading activity at Lantheus will often cluster around high‑impact events: NDA acceptances/PDUFA dates, pivotal trial readouts, acquisition announcements/closings, quarterly earnings and public guidance changes—events that materially affect PYLARIFY pricing/reimbursement and short‑shelf‑life supply dynamics. Expect routine equity exercises and sales to cover tax withholding after vesting (noted in the 10‑Q) and potential opportunistic trades near share repurchase windows; executives may also use 10b5‑1 plans to manage trading around predictable vesting and blackout periods. Regulatory sensitivity in this industry (FDA, NRC, EMA, GDPR) plus concentrated supplier risks create frequent sources of material nonpublic information, so Section 16 reporting, blackout compliance and careful timing of trades are especially important for insiders.